MX2017016103A - Factor estimulador de colonia de granulocito (gcsf) pegilado. - Google Patents
Factor estimulador de colonia de granulocito (gcsf) pegilado.Info
- Publication number
- MX2017016103A MX2017016103A MX2017016103A MX2017016103A MX2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A MX 2017016103 A MX2017016103 A MX 2017016103A
- Authority
- MX
- Mexico
- Prior art keywords
- gcsf
- stimulating factor
- colony stimulating
- granulocyte colony
- pegylated granulocyte
- Prior art date
Links
- 108010006260 pegylated granulocyte colony-stimulating factor Proteins 0.000 title 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 abstract 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174373P | 2015-06-11 | 2015-06-11 | |
| US201562184042P | 2015-06-24 | 2015-06-24 | |
| PCT/US2016/037278 WO2016201448A2 (en) | 2015-06-11 | 2016-06-13 | Pegylated granulocyte colony stimulating factor (gcsf) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016103A true MX2017016103A (es) | 2018-05-22 |
Family
ID=57504855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016103A MX2017016103A (es) | 2015-06-11 | 2016-06-13 | Factor estimulador de colonia de granulocito (gcsf) pegilado. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160361426A1 (enExample) |
| EP (1) | EP3307757A4 (enExample) |
| JP (1) | JP2018519359A (enExample) |
| KR (1) | KR20180017104A (enExample) |
| CN (1) | CN107949565A (enExample) |
| AU (1) | AU2016277147A1 (enExample) |
| CA (1) | CA2988988A1 (enExample) |
| IL (1) | IL256167A (enExample) |
| MX (1) | MX2017016103A (enExample) |
| RU (1) | RU2018100425A (enExample) |
| WO (1) | WO2016201448A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011630A (es) * | 2020-03-20 | 2022-12-02 | Amgen Inc | Determinación del extremo n libre del pegfilgrastim utilizando una proteasa ácida. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
| US6565841B1 (en) * | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| AU1676992A (en) * | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| WO2003006501A2 (en) * | 2001-07-11 | 2003-01-23 | Maxygen Holdings, Ltd. | G-csf conjugates |
| US7144978B2 (en) * | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| ES2536710T3 (es) * | 2002-03-25 | 2015-05-27 | Arimed Inc. | Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A |
| US7892745B2 (en) * | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| AU2004296855B2 (en) * | 2003-12-03 | 2011-01-06 | Ratiopharm Gmbh | Glycopegylated Granulocyte Colony Stimulating Factor |
| CA2607844C (en) * | 2005-06-01 | 2012-07-10 | Maxygen Holdings Ltd. | Pegylated g-csf polypeptides and methods of producing same |
| CA2617064A1 (en) * | 2005-08-04 | 2007-02-15 | Nektar Therapeutics Al, Corporation | Conjugates of a g-csf moiety and a polymer |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US20110104100A1 (en) * | 2007-10-04 | 2011-05-05 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
| CN101602801A (zh) * | 2008-06-13 | 2009-12-16 | 杭州九源基因工程有限公司 | 聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体 |
| TW201138831A (en) * | 2009-09-30 | 2011-11-16 | Prolong Pharmaceuticals Inc | Modified granulocyte colony stimulating factor (G-CSF) |
| WO2011075606A2 (en) * | 2009-12-18 | 2011-06-23 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| CN104109235B (zh) * | 2014-05-30 | 2017-07-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质 |
-
2016
- 2016-06-13 CN CN201680047209.0A patent/CN107949565A/zh active Pending
- 2016-06-13 RU RU2018100425A patent/RU2018100425A/ru not_active Application Discontinuation
- 2016-06-13 US US15/181,333 patent/US20160361426A1/en not_active Abandoned
- 2016-06-13 JP JP2018516407A patent/JP2018519359A/ja active Pending
- 2016-06-13 EP EP16808533.0A patent/EP3307757A4/en not_active Withdrawn
- 2016-06-13 MX MX2017016103A patent/MX2017016103A/es unknown
- 2016-06-13 KR KR1020187000596A patent/KR20180017104A/ko not_active Withdrawn
- 2016-06-13 WO PCT/US2016/037278 patent/WO2016201448A2/en not_active Ceased
- 2016-06-13 CA CA2988988A patent/CA2988988A1/en not_active Abandoned
- 2016-06-13 AU AU2016277147A patent/AU2016277147A1/en not_active Abandoned
-
2017
- 2017-12-07 IL IL256167A patent/IL256167A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018519359A (ja) | 2018-07-19 |
| EP3307757A4 (en) | 2019-03-13 |
| CA2988988A1 (en) | 2016-12-15 |
| WO2016201448A3 (en) | 2017-02-09 |
| AU2016277147A1 (en) | 2018-01-18 |
| US20160361426A1 (en) | 2016-12-15 |
| EP3307757A2 (en) | 2018-04-18 |
| IL256167A (en) | 2018-04-30 |
| RU2018100425A3 (enExample) | 2019-11-21 |
| CN107949565A (zh) | 2018-04-20 |
| KR20180017104A (ko) | 2018-02-20 |
| RU2018100425A (ru) | 2019-07-15 |
| WO2016201448A2 (en) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4529952A3 (en) | Parp1 inhibitors | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| SA520411202B1 (ar) | مترافقات سيتوكين لعلاج أمراض المناعة الذاتية | |
| EP3173092A3 (en) | Rna containing composition for treatment of tumor diseases | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| MA46245A (fr) | Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron) | |
| PH12018500719A1 (en) | Oligonucleotide compositions and methods thereof | |
| EP4219713A3 (en) | Products and compositions | |
| MY209471A (en) | Interleukin-2 agents and uses thereof | |
| MA40241A (fr) | Compositions enrichies stéréochimiquement pour l'administration d'acides nucléiques | |
| EP4406544A3 (en) | Cellular targeted active ingredient delivery system | |
| EP4310500A3 (en) | Methods and compositons for the activation of gamma-delta t-cells | |
| EP2574170A4 (en) | IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS | |
| JOP20210305A1 (ar) | صيغ إيماتينيب وتصنيعها واستخداماتها | |
| PH12019501193A1 (en) | Use of chelating agents for improving color stability of resorcinol | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| WO2020123816A3 (en) | Anellosomes and methods of use | |
| ZA202000375B (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| WO2016149659A3 (en) | Antisense-induced exon exclusion in myostatin | |
| MX2019001907A (es) | Composicion para el cuidado de telas que comprende copolimeros de glicerido. | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| WO2015159155A3 (en) | Novel ademetionine formulations | |
| IL286319A (en) | Chitosan polyplex-based localized expression of il-12 alone or in combination with type-i ifn inducers for treatment of mucosal cancers | |
| PH12021551428A1 (en) | Recombinant avian herpes viruses containing multiple foreign genes | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib |